OPV in a child on prednisone for nephrotic syndrome
No—do not give OPV to a child currently receiving prednisone for nephrotic syndrome; use inactivated polio vaccine (IPV) instead. 1, 2
- Rationale (morbidity/mortality/QOL prioritized):
- Live vaccines (including OPV) are contraindicated while on systemic corticosteroids at immunosuppressive doses; defer live vaccines until prednisone is below 1 mg/kg/day (or <20 mg/day) or 2 mg/kg on alternate days (<40 mg on alternate days) and has been stopped/low for an adequate interval, per KDIGO pediatric NS guidance 1.
- OPV poses a risk of vaccine-associated paralytic poliomyelitis (VAPP) to recipients and close contacts; this risk is eliminated by IPV schedules and underlies policy shifts away from OPV in immunocompromised settings and contacts 2. FDA labeling supports IPV as safe/effective and notes elimination of VAPP with IPV-only schedules 2.
- Case evidence documents severe VAPP in a household contact on chronic steroids after infant OPV, reinforcing avoidance when patient or close contacts are immunosuppressed 3.
Action algorithm
- If on prednisone at immunosuppressive doses (≥1 mg/kg/day or ≥20 mg/day, or ≥2 mg/kg/40 mg on alternate days):
- If off steroids or on low, non-immunosuppressive doses below KDIGO thresholds and an adequate washout has occurred:
- Ensure other recommended inactivated vaccines (influenza annually, pneumococcal) are up to date to reduce serious infections and relapse risk triggers 1.
Pitfalls/caveats
- Do not rely on OPV “safety” data from non-immunosuppressed renal patients; immunosuppression changes risk calculus 4.
- Avoid OPV in close contacts of the child on steroids to prevent secondary transmission and VAPP risk 1, 3.
- OPV/nOPV policies vary by country; when OPV is in use locally, explicitly request IPV for the patient and counsel the family accordingly 2.